Centogene incurred a net loss of -€11.9m for the second quarter, which was wider by -48% compared to 2Q 2021. On a per-share basis, loss was -€0.44 (vs. - €0.37 loss in the year-ago quarter).
Revenue plunged -78% year-over-year to €11.2m in the quarter, missing analysts’ estimates by 3.1%.
a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies
Industry MedicalSpecialties